Mr. Handrinos is described as "one of the best life sciences lawyers in Boston." Legal 500 USA

Peter N. Handrinos

Boston | New York
  • John Hancock Tower, 27th Floor
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA

Peter Handrinos is Global Co-Chair of the Life Sciences Industry Group. He practices corporate and securities law, with an emphasis on mergers and acquisitions, capital markets and venture capital transactions for life sciences and technology companies. Mr. Handrinos advises both public and private companies in connection with a broad range of matters, including:

  • IPOs
  • Follow-on offerings
  • Strategic investments
  • 144A offerings
  • Cash and stock mergers
  • Tender offers
  • Going-private transactions

He counsels numerous start-up companies and venture capital firms in venture capital financings. Mr. Handrinos also regularly represents investment banks in connection with capital markets transactions. A significant portion of his practice involves general corporate work for ongoing clients on matters such as SEC compliance, securities and disclosure issues, and corporate governance matters.

The Legal 500 USA described Mr. Handrinos as “one of the best life sciences lawyers in Boston.” He has been recognized as a leader in Corporate/M&A by Chambers USA since 2007, where he is also described as a “superb attorney – exceptionally bright, attentive to details and remarkably hard working.” He has been listed in the 2012 through 2014 editions of Best Lawyers in America as a leader in mergers and acquisitions

Mr. Handrinos's has advised the following clients on their IPOs: 

  • Seres Therapeutics
  • Press Ganey
  • Valeritas
  • T2 Biosystems
  • Radius Health
  • BIND Therapeutics
  • Aratana Therapeutics

Mr. Handrinos has advised the underwriters for the following IPOs: 

  • Aclaris Therapeutics
  • American Renal Holdings
  • Blueprint Medicines Corporation
  • CoLucid Pharmaceuticals
  • Flex Pharma
  • Collegium Pharmaceutical
  • Agile Therapeutics
  • Akebia Therapeutics
  • Auspex Pharmaceuticals
  • Applied Genetic Technologies Corp
  • Trevena
  • Cara Therapeutics
  • Mazor Robotics
  • Tetraphase Pharmaceuticals

In addition, Mr. Handrinos’s representative transactions include representing:

  • Jefferies and Barclays in a follow-on public offering by Trevena
  • Stifel and Piper in a follow-on public offering by Cara Therapeutics
  • BofA Merrill Lynch and Cowen in a follow-on public offering by Dyax Corp.
  • UBS and Morgan Stanley in a follow-on offering by Akebia Therapeutics
  • Aratana Therapeutics in its
    • PIPE and follow-on offerings
    • acquisition of Okapi Sciences BV
    • acquisition of Vet Therapeutics Inc.
  • Epirus Biopharmaceuticals in its merger with Zalicus and follow-on offering
  • Seres Therapeutics in its US$48 million Series C and US$65 million Series D financings
  • Radius Health in its follow-on offerings
  • BIND Therapeutics in its follow-on offerings
  • Morgan Stanley and BAML in a follow-on offering by Sarepta Therapeutics
  • BMO and Stifel in follow-on offerings by Tetraphase Pharmaceuticals
  • Chiasma in its US$595 million collaboration with Roche
  • J.P. Morgan, Cowen, and Jefferies in a follow-on offering by ARIAD
  • Morgan Stanley, Barclays and Goldman Sachs in IPO by Sensata Technologies Holding N.V.
  • MPM Capital in connection with the financing and collaboration between Astellas and Mitokyne
  • MPM Capital in connection with the financing and collaboration between Novartis and Sideris